Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Summit takes clinical trial participant search online

Hopes to broaden reach of its Duchenne muscular dystrophy study

Digital pharmaSummit is looking to reach potential clinical trial volunteers online via a new resource on utrophin modulation, whose potential as a treatment for Duchenne muscular dystrophy (DMD) the UK biopharma is investigating.

Utrophintrials.com provides information on utrophin and Summit's utrophin modulator clinical trials, including for its lead candidate the orphan drug ezutromid, which is currently in a phase IIa trial.

Glyn Edwards, Summit's chief executive officer, said: “We recognise the dedication and engagement of the DMD community in the search for solutions for this fatal muscle wasting disease, and with this website, seek to provide this community with access to important information about our utrophin modulator programme and clinical trials.

“We are committed to broadening our relationship with the DMD community as we advance ezutromid and other utrophin modulators, which may have the potential to treat all patients with DMD.”

A progressive muscle wasting disease, DMD affects around 50,000 boys and young men in the developed world and currently has no cure.

If Summit can bring ezutromid to market it will compete with PCT Therapeutics' Translarna, which was recommended by NICE in England and Wales earlier this year, and potentially Santhera Pharmaceuticals' delayed Raxone.

13th September 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics